| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
We have demonstrated that low grade inflammation, microinflammation, is involved in the pathogenesis of diabetic nephropathy as well as of atherosclerosis. We have recently reported that anti-inflammatory agents such as statin and thiazolidinedione show renoprotective effects through anti-inflammatory actions in diabetic animals. In this study, 1) We induced diabetes into osteopontin knockout(KO) mice. Osteopontin KO mice showed the improvement of tissue injuries and inflammatory reactions in the kidney. 2) We found that GLP-1 receptor is expressed on monocte/macrophage and glomerular endothelial cells. GLP-1 receptor agonist showed renoprotective effects on diabetic rats through anti-inflammatory actions. These results suggest that osteopontin play a role in the pathogenesis of diabetic nephropathy and GLP-1 receptor agonist might be beneficial for the treatment of diabetic nephropathy.
|
